Yes, there is a vaccine for HPV, and it’s one of the most effective cancer-prevention tools available. The current vaccine used in the United States, Gardasil 9, protects against nine strains of human papillomavirus, including the types responsible for roughly 90% of HPV-related cancers. Early vaccination has been shown to reduce the overall risk of developing cervical cancer by more than 80%.
What the Vaccine Protects Against
HPV isn’t a single virus. There are over 200 types, and a handful of them cause the vast majority of HPV-related health problems. Gardasil 9 targets nine of the most dangerous and common strains: types 16, 18, 31, 33, 45, 52, and 58 (which cause cancers) and types 6 and 11 (which cause genital warts).
The cancers prevented by HPV vaccination go well beyond cervical cancer. HPV also causes cancers of the anus, penis, and the back of the throat (including the base of the tongue and tonsils) in both men and women. Throat cancers linked to HPV have been rising steadily in recent decades, making vaccination relevant for everyone, not just women.
How the Vaccine Works
The vaccine contains no live virus and cannot cause an HPV infection. Instead, it uses virus-like particles, which are protein shells that look like HPV on the outside but are completely empty on the inside. Your immune system recognizes these particles as a threat and builds antibodies against them. If you’re later exposed to the real virus, your body already knows how to fight it off. The protection is thought to come from this antibody response, and more than 15 years of follow-up data show that it lasts.
Who Should Get It and When
The ideal time to get vaccinated is before any exposure to HPV, which is why routine vaccination is recommended starting at age 9. The number of doses you need depends on when you start:
- Ages 9 through 14: Two doses, spaced 6 to 12 months apart.
- Ages 15 through 26: Three doses, given at 0, 1 to 2, and 6 months.
- Ages 27 through 45: Three doses on the same schedule, though vaccination in this age range is typically a shared decision between you and your doctor based on your individual risk.
If the two-dose series is given with less than five months between shots, a third dose is needed. People with weakened immune systems, including those living with HIV, need three doses regardless of age.
Globally, vaccination access is expanding. The World Health Organization confirmed in late 2024 that a fourth HPV vaccine product is now approved for single-dose use, and 57 countries have already adopted a single-dose schedule. This shift is making it far easier to vaccinate populations in lower-resource settings where return visits for second and third doses can be a barrier.
How Effective It Really Is
The numbers are striking. Among vaccinated populations, cervical precancers (the abnormal cell changes that lead to cancer if untreated) have dropped by about 40%, and the overall risk of developing cervical cancer has fallen by more than 80%. Australia, which launched one of the earliest national HPV vaccination programs, is on track to become the first country to eliminate cervical cancer entirely, with a target date of 2035.
That said, the vaccine protects against most but not all high-risk HPV strains. This is why routine cervical cancer screening (Pap smears or HPV tests) is still recommended even for vaccinated individuals. The combination of vaccination plus screening provides the strongest protection.
Side Effects and Safety
The most common side effects are mild: soreness, redness, or swelling at the injection site, along with occasional dizziness, nausea, or headache. Fainting can happen after any vaccine in adolescents, so clinics typically ask teens to sit or lie down for about 15 minutes afterward.
Serious allergic reactions (anaphylaxis) occur at a rate of about 3 cases per million doses, which is consistent with other routine vaccines. Beyond that, no confirmed adverse events have occurred at higher-than-expected rates following HPV vaccination. The U.S. monitors vaccine safety through multiple independent systems, and more than 15 years of surveillance data consistently support the vaccine’s safety profile.
Why It Matters for Boys and Men
HPV vaccination is sometimes still thought of as something only girls need. That’s outdated. HPV causes cancers of the penis, anus, and throat in men, and oropharyngeal cancer linked to HPV is now more common in men than cervical cancer is in women in some countries. Vaccinating boys also reduces transmission to future partners, which strengthens protection at the population level. The dosing schedule and recommendations are the same regardless of sex.
If You’re Already an Adult
Many adults in their 20s, 30s, or even 40s wonder whether it’s too late. If you’re 26 or younger and haven’t been vaccinated, the recommendation is straightforward: get the three-dose series. Between ages 27 and 45, the vaccine is still available, but the benefit depends on your circumstances. Most adults in this range have already been exposed to at least some HPV strains through normal sexual contact, which reduces (but doesn’t eliminate) the potential benefit. If you have a new partner, multiple partners, or other risk factors, vaccination may still be worthwhile. The conversation is worth having with your healthcare provider, because partial protection against strains you haven’t encountered yet is still valuable protection.